Clinical Trials Logo

Glabellar Frown Lines clinical trials

View clinical trials related to Glabellar Frown Lines.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05766683 Active, not recruiting - Clinical trials for Glabellar Frown Lines

Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines

Start date: March 14, 2023
Phase: Phase 1
Study type: Interventional

STUDY QUESTION: Does the depth of injection of onabotulinumtoxinA neurotoxin in the glabellar complex affect efficacy of the BoTN for the improvement of glabellar frown lines? STUDY AIM - Primary objective: Compare the efficacy of onabotulinumtoxinA neurotoxin injected at the depth of 2mm vs 4mm for the improvement of glabellar lines - Secondary objective: Determine any adverse effects of onabotulinumtoxinA neurotoxin injected at the depth of 2mm vs 4mm RATIONALE FOR THE PROJECT: Although the use of BoTN for treatment of glabellar lines has long been established as safe and effective, the optimal depth of injection has not been established. Our project hopes to establish the optimal depth of injection for onabotulinumtoxinA neurotoxin for maximal improvement of glabellar lines with minimal adverse effects

NCT ID: NCT05623410 Active, not recruiting - Clinical trials for Glabellar Frown Lines

Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines

Start date: October 11, 2022
Phase: Phase 3
Study type: Interventional

Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Xeomin for a total of 16 weeks after the administration in treatment of glabellar frown lines.

NCT ID: NCT05565950 Active, not recruiting - Clinical trials for Glabellar Frown Lines

AI-09 In Subjects With Glabellar Lines, GL-101

Start date: October 3, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

AI-09 In Subjects with Glabellar Lines

NCT ID: NCT05146999 Active, not recruiting - Clinical trials for Glabellar Frown Lines

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

Start date: May 9, 2022
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP treatment for subjects with moderate to severe glabellar lines

NCT ID: NCT04715048 Active, not recruiting - Clinical trials for Glabellar Frown Lines

Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines

Start date: January 1, 2021
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to compare the efficacy and side effects of Botox and Jeuveau for glabellar lines.

NCT ID: NCT04281745 Active, not recruiting - Clinical trials for Glabellar Frown Lines

Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®

Start date: October 17, 2019
Phase: Phase 4
Study type: Interventional

This study evaluates the long-term safety and efficacy of CORETOX in the treatment of moderate to severe glabellar lines.

NCT ID: NCT03440671 Active, not recruiting - Clinical trials for Glabellar Frown Lines

The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines

Start date: November 30, 2017
Phase: Phase 3
Study type: Interventional

A Phase Ⅲ Clinical Trial to Compare the Safety and Efficacy of Hutox versus Botox® in Subject with Moderate to Severe Glabellar Lines